Skip to main content
  • Saved

made a Post

Abstract 709: The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers

Abstract 709: The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers

Source :

https://cancerres.aacrjournals.org/content/80/16_Supplement/709

Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Background: KRAS is the most common oncogene in lung cancer, but has historically been considered undruggable. The recent development of mutant-selective KRAS G12C inhibitors has for the first time created potential therapeutic opportunities for this unmet need.